Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.
SAPAS (603168.SH) announcement, recently, the company has received approval from the National Medical Products Administration to issue bromfenac...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company received the "Drug Registration Certificate" for the sodium bromfenac eye drops issued by the National Medical Products Administration. The sodium bromfenac eye drops approved this time are used for symptomatic treatment of inflammatory diseases of the external and anterior parts of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Related Articles
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
